A Phase II Study of OXALIPLATIN and GEMCITABINE in Combination with IFOSFAMIDE plus RITUXIMAB (R-GIFOX) as 2nd-line Chemotherapy in Relapsed and Primary Refractory Lymphoma.

Trial Profile

A Phase II Study of OXALIPLATIN and GEMCITABINE in Combination with IFOSFAMIDE plus RITUXIMAB (R-GIFOX) as 2nd-line Chemotherapy in Relapsed and Primary Refractory Lymphoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2011

At a glance

  • Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Rituximab (Primary) ; Ifosfamide
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms R-GIFOX
  • Most Recent Events

    • 27 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top